ABIOMED Receives Consensus Recommendation of “Buy” from Brokerages (NASDAQ:ABMD)
Shares of ABIOMED (NASDAQ:ABMD) have been given an average recommendation of “Buy” by the eight analysts that are presently covering the company, Analyst Ratings Network.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $26.83.
Shares of ABIOMED (NASDAQ:ABMD) traded up 0.05% during mid-day trading on Friday, hitting $21.21. The stock had a trading volume of 31,205 shares. ABIOMED has a 52-week low of $18.15 and a 52-week high of $30.77. The stock’s 50-day moving average is $23.86 and its 200-day moving average is $26.42. The company has a market cap of $844.4 million and a P/E ratio of 117.78.
ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, May 1st. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.08 by $0.01. The company had revenue of $50.40 million for the quarter, compared to the consensus estimate of $50.93 million. During the same quarter last year, the company posted $0.09 earnings per share. ABIOMED’s revenue was up 15.5% compared to the same quarter last year. On average, analysts predict that ABIOMED will post $0.30 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ABMD shares. Analysts at Zacks reiterated a “neutral” rating on shares of ABIOMED in a research note on Thursday. They now have a $23.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of ABIOMED in a research note on Monday, March 24th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating in a research note on Friday, March 21st.
ABIOMED, Inc is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.